Table 3

Overall survival in groups without or with adjuvant chemotherapy
No adjuvant chemotherapy group Adjuvant chemotherapy group
No. (%) 5-Y OS rate (%) P No. (%) 5-Y OS rate (%) P
All patients 36 (100) 68.3 57 (100) 52.3
ERCC1 status 0.083 0.074
Positive 20 (55.6) 84.0 34 (59.6) 41.6
Negative 16 (44.4) 49.2 23 (40.4) 71.8
Sex 0.080 0.14
Male 32 (88.9) 70.6 47 (82.5) 46.2
Female 4 (11.1) 50.0 10 (17.5) 77.8
Age at operation 0.40 0.99
≥ 65 years 24 (66.7) 70.0 16 (28.1) 60.3
< 65 years 12 (33.3) 61.1 41 (71.9) 51.2
T stage 0.21 0.57
T1-T2 15 (41.7) 83.6 4 (7.0) 50.0
T3-T4 21 (58.3) 59.2 53 (93.0) 52.9
N stage 0.10 0.73
N0 32 (88.9) 70.9 29 (50.9) 47.7
N1-3 4 (11.1) 50.0 28 (49.1) 59.1
Histologic type 0.088 0.21
Squamous differentiation 2 (5.6) 50.0 9 (15.8) 77.8
Other types 34 (94.4) 69.8 48 (84.2) 46.8
Pathologic Grade* 0.35 0.47
G2 3 (8.3) 100.0 7 (12.3) 71.4
G3 33 (91.7) 65.7 50 (87.7) 50.2

*1973 WHO grading.

Sun et al.

Sun et al. BMC Cancer 2012 12:187   doi:10.1186/1471-2407-12-187

Open Data